NEW YORK, Jan. 30, 2012  /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Biomarker Partnering Terms and Agreements

http://www.reportlinker.com/p0471283/Biomarker-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics

Report description The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 550 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in biomarker partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

Key benefits Biomarker Partnering Terms and Agreements provides the reader with the following Key benefits:

• In-depth understanding of biomarker deal trends since 2007

• Access to headline, upfront, milestone and royalty data

• Analysis of the structure of biomarker agreements with numerous real life case studies

• Comprehensive access to over 550 actual biomarker contracts entered into by the world's biopharma companies

• Detailed access to actual biomarker contracts enter into by the leading fifty bigpharma companies

• Insight into the terms included in a biomarker agreement, together with real world clause examples

• Understand the key deal terms companies have agreed in previous deals

• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

o Trends in biomarker dealmaking in the biopharma industry since 2007

o Analysis of biomarker deal structure

o Access to headline, upfront, milestone and royalty data

o Case studies of real-life biomarker deals

o Access to over 550 biomarker contract documents

o The leading biomarker deals by value since 2007

o Most active biomarker dealmakers since 2007

o The leading biomarker partnering resources

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

o Company A-Z

o Headline value

o Stage of development at signing

o Deal component type

o Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 550 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

o What are the precise biomarker rights granted or optioned?

o What is actually granted by the agreement to the partner company?

o What exclusivity is granted?

o What is the payment structure for the deal?

o How are sales and payments audited?

o What is the deal term?

o How are the key terms of the agreement defined?

o How are IPRs handled and owned?

o Who is responsible for commercialization?

o Who is responsible for development, supply, and manufacture?

o How is confidentiality and publication managed?

o How are disputes to be resolved?

o Under what conditions can the deal be terminated?

o What happens when there is a change of ownership?

o What sublicensing and subcontracting provisions have been agreed?

o Which boilerplate clauses does the company insist upon?

o Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

o Which jurisdiction does the company insist upon for agreement law?

Number of pages:

The report is comprised of 594 pages.

Executive Summary Chapter 1 – IntroductionChapter 2 – Trends in biomarker dealmaking 2.1. Introduction

2.2. Biomarker partnering over the years

2.3. Bigpharma biomarker dealmaking activity

2.4. Bigpharma not active in biomarkers

2.5. Biomarker partnering by deal type

2.6. Biomarker partnering by disease type

2.7 Average deal terms for biomarkers

2.7.1 Biomarker headline values

2.7.2 Biomarker upfront payments

2.7.3 Biomarker milestone payments

2.7.4 Biomarker royalty rates

Chapter 3 – Leading biomarker deals 3.1. Introduction

3.2. Top biomarker deals by value

3.3. Top biomarker deals involving bigpharma

Chapter 4 – Bigpharma biomarker deals 4.1. Introduction

4.2. How to use bigpharma biomarker partnering deals

4.3. Bigpharma biomarker partnering company profiles

Abbott

Actavis

Alcon Labs

Allergan

Amgen

Apotex

Astellas

AstraZeneca

Baxter International

Bayer

Bayer Healthcare

Bayer Schering Pharma

Bayer Vital

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

Cephalon

Chugai

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Forest Laboratories

Genzyme

Genzyme Genetics

Gilead Sciences

GlaxoSmithKline

Hospira

Johnson & Johnson

Janssen Pharmaceutica NV

Kyowa Hakko Kirin

Lundbeck

Menarini

Merck & Co

Merck Sharpe & Dohme

Merck KGaA

Merck KGaA

Merck Serono

Mitsubishi Tanabe

Mylan

Novartis

Novartis Molecular Diagnostics

Novo Nordisk

Nycomed Pharma

Otsuka

Pfizer

Roche

Roche Applied Science

Roche Diagnostics

Roche Molecular Systems

Roche NimbleGen

Genentech

Sanofi

Servier

Shionogi

Shire

Stada

Takeda

Teva

UCB

Warner Chilcott

Watson

Chapter 5 – Biomarker dealmaking directory 5.1. Introduction

5.2. Company A-Z

5.3. By stage of development

Discovery

Preclinical

Phase I

Phase II

Phase III

Regulatory

Marketed

5.4. By deal type

Asset purchase

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Manufacturing

Manufacturing - OEM

Marketing

Option

Promotion

Research

Settlement

Spin out

Sub-license

Supply

Termination

5.5. By therapy area

Cardiovascular

Central Nervous System

Dental

Dermatology

Gastrointestinal

Genetic disorders

Genitourinary

Hematology

Hospital care

Immunology

Infectives

Inflammatory

Metabolic

Musculoskeletal

Oncology

Respiratory

Chapter 6 – Biomarker partnering resource center 6.1. Online biomarker partnering

6.2. Biomarker partnering events

6.3. Further reading on biomarker dealmaking

Appendices Appendix 1 – Deal type definitions

Appendix 2 – Example biomarker partnering agreement

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Reports

Table of figures Figure 1: Biomarker partnering since 2007

Figure 2: Bigpharma – top 50 – biomarker deals 2007 to 2011

Figure 3: Bigpharma diagnostic deal frequency – 2007 to 2011

Figure 4: Inactive bigpharma in biomarkers 2007-2011

Figure 5: Biomarker partnering by deal type since 2007

Figure 6: Biomarker partnering by disease type since 2007

Figure 7: Biomarker partnering by oncology target since 2007

Figure 8: Biomarker deals with a headline value

Figure 9: Biomarker deal headline value distribution, US$million – 2007-2011 – Discovery stage

Figure 10: Biomarker deal headline value distribution, US$million – 2007-2011 – Discovery stage - detail

Figure 11: Biomarker deals with upfront payment values

Figure 12: Biomarker deals with milestone payments

Figure 13: Biomarker deals with royalty rates, %

Figure 14: Top biomarker deals by value since 2007

Figure 15: Top biomarker deals signed by bigpharma value since 2007

Figure 16: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Cardiovascular)

Figure 17: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Central Nervous System)

Figure 18: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Dental)

Figure 19: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Dermatology)

Figure 20: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Gastrointestinal)

Figure 21: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Genetic disorders)

Figure 22: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Genitourinary)

Figure 23: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hematology)

Figure 24: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hospital care)

Figure 25: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Immunology)

Figure 26: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Infectives)

Figure 27: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Inflammatory)

Figure 28: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Metabolic)

Figure 29: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Musculoskeletal)

Figure 30: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Oncology)

Figure 31: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Respiratory)

Figure 32: Online partnering resources

Figure 33: Forthcoming partnering events

Figure 34: Deal type definitions

Figure 35: Biomarker partnering agreement between GlaxoSmithKline and Response Genetics, May 2010

To order this report: Genomics Industry: Biomarker Partnering Terms and Agreements

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker

Back to top

RELATED LINKS
http://www.reportlinker.com